Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Aspire Biopharma Holdings, Inc. - Warrant (NQ:ASBPW)

0.0183 -0.0022 (-10.73%)

Streaming Delayed Price Updated: 3:41 PM EDT, Aug 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	12,713
Open	0.0191
Bid (Size)	0.0183 (26,100)
Ask (Size)	0.0191 (100)
Prev. Close	0.0205
Today's Range	0.0183 - 0.0200
52wk Range	0.0100 - 0.0822
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

Today 8:15 EDT

From Aspire Biopharma Holdings, Inc.

Via ACCESS Newswire

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

August 10, 2026

From Aspire Biopharma Holdings, Inc.

Via ACCESS Newswire

Performance

YTD	-1.6%	-1.6%
1 Month	-23.4%	-23.4%
3 Month	-4.2%	-4.2%
6 Month	+1.7%	+1.7%
1 Year	-54.2%	-54.2%

More News

Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)

July 20, 2026

From Aspire Biopharma Holdings, Inc.

Via ACCESS Newswire

Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs

June 24, 2026

From Aspire Biopharma Holdings, Inc.

Via ACCESS Newswire

Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

June 12, 2026

Via ACCESS Newswire

Aspire Biopharma Issues Shareholder Letter

May 28, 2026

Via ACCESS Newswire

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

May 27, 2026

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

May 07, 2026

Via ACCESS Newswire

Aspire Biopharma Announces $5.0 Million Share Repurchase Program

April 27, 2026

Via ACCESS Newswire

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

April 20, 2026

Via ACCESS Newswire

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

April 17, 2026

Via ACCESS Newswire

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

April 16, 2026

Via ACCESS Newswire

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

April 15, 2026

Via ACCESS Newswire

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

March 19, 2026

Via ACCESS Newswire

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

March 17, 2026

Via ACCESS Newswire

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

March 12, 2026

Via ACCESS Newswire

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

March 10, 2026

Via ACCESS Newswire

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

March 03, 2026

Via ACCESS Newswire

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

February 25, 2026

Via ACCESS Newswire

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

February 20, 2026

Via ACCESS Newswire

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

February 19, 2026

Via ACCESS Newswire

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

February 17, 2026

Via ACCESS Newswire

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

February 13, 2026

Via ACCESS Newswire

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

February 12, 2026

Via ACCESS Newswire

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

February 11, 2026

Via ACCESS Newswire

Frequently Asked Questions

Is Aspire Biopharma Holdings, Inc. - Warrant publicly traded?

Yes, Aspire Biopharma Holdings, Inc. - Warrant is publicly traded.

What exchange does Aspire Biopharma Holdings, Inc. - Warrant trade on?

Aspire Biopharma Holdings, Inc. - Warrant trades on the Nasdaq Stock Market

What is the ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant?

The ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant is ASBPW on the Nasdaq Stock Market

What is the current price of Aspire Biopharma Holdings, Inc. - Warrant?

The current price of Aspire Biopharma Holdings, Inc. - Warrant is 0.0183

When was Aspire Biopharma Holdings, Inc. - Warrant last traded?

The last trade of Aspire Biopharma Holdings, Inc. - Warrant was at 08/13/26 03:41 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.